

# New York State Hepatitis C Care and Treatment Initiative

Data Brief #2, May 2018

- The New York State Department of Health (NYSDOH) Hepatitis C (HCV) Care and Treatment Initiative funds 15 primary care sites throughout NYS to provide linkage to care services along with HCV care, treatment, and supportive services.
- This report highlights outcomes from the Initiative's second year (April 2016 - March 2017).

## Program Highlights



**1,790 patients enrolled,**  
**81% ever linked to a medical provider,**  
**67% linked within 30 days.**



**54% of patients linked to care initiated treatment.**

Of those eligible, black patients were 1.5 times more likely to initiate treatment and 1.7 times more likely to complete treatment and be assessed for SVR\* than white patients.



**Among those who initiated treatment, 90% completed treatment.**

Patients who reported past injection drug use were 1.7 times more likely to complete treatment and be assessed for SVR than patients who currently use drugs.




**97% of patients who initiated treatment and had their final HCV RNA test were cured of HCV.**

\* SVR (Sustained Virologic Response) is defined as the absence of HCV RNA 12 weeks post treatment completion. Patients who achieve SVR are considered cured of HCV disease.

## HCV Care Cascade\*

Of 1,790 patients with positive HCV antibody test enrolled:



\* Data for patients enrolled in programs from 4/2016 through 3/2017 and extracted from AIDS Institute Reporting System (AIRS) on 2/23/2018. Percent denominators are N from previous bar.

\*\* Patients starting treatment are limited to those with reported positive RNA tests.



Department  
of Health

AIDS  
Institute


Contact: [hepatabc@health.ny.gov](mailto:hepatabc@health.ny.gov)

For more information, please visit: [health.ny.gov/hepatitis](http://health.ny.gov/hepatitis)

Produced: The Office of Program Evaluation and Research

Date: May 2018


## Patient Characteristics\* (N=1,790)



\* Injection drug use (IDU) and birth cohort (born from 1945-1965) were the most commonly reported risk factors. Almost three-quarters of patients reported a history of IDU and half were born from 1945 to 1965.

\*\* Includes Asian, Hawaiian/Pacific Islander, Native American/Alaskan Native, and Other Race/Ethnicity.


### HCV Treatment Regimens (n=706)\*



### HCV Treatment Regimens

Note: Zepatier=Elbasvir/Grazoprevir; Harvoni=Ledipasvir/Sofosbuvir; Epclusa=Sofosbuvir/Velpatasvir; Daklinza=Daclatasvir

### Linkage to Care Results (n=1,790)



### Time from Enrollment to Medical Encounter

## CONCLUSIONS

- The NYSDOH Hepatitis C Care and Treatment Initiative continues to serve as a successful model for increasing access to HCV care and treatment and increasing the number of persons cured of HCV.
- Barriers preventing or delaying treatment initiation continue and include other comorbid conditions, such as active substance use.
- With the new, highly effective, HCV medications, primary care providers are able to care for, treat and cure persons infected with HCV.